 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Diamyd Medical AB engages in the development of pharmaceutical products for the treatment of diabetes and other serious inflammatory diseases. Its pipeline includes Diamyd and Remygen which targets the underlying causes of diabetes, dysfunction, and loss of the pancreatic beta cells. It also develops and invests in stem cell and medical technology. The company was founded by Anders Essen-Moller in 1996 and is headquartered in Stockholm, Sweden.

Market Cap	$162.38M
52-Wk High	$1.70
52-Wk Low	$1.70

DYMDF Diamyd Medical AB - Ordinary Shares - Class B

About

Feed

News

Fundamentals